Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer

Por Costa, Daniel B.
Publicado no Transl Lung Cancer Res (2014)

Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements

Por Costa, Daniel B.
Publicado no Transl Lung Cancer Res (2016)

Resistance to ALK inhibitors: Pharmacokinetics, mutations or bypass signaling?

Por Costa, Daniel B.
Publicado no Cell Cycle (2016)

Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M

Por Costa, Daniel B., Kobayashi, Susumu S.
Publicado no Transl Lung Cancer Res (2015)

Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities

Por Gaughan, Elizabeth M., Costa, Daniel B.
Publicado em 2011

Lazarus-type response to crizotinib in a patient with poor performance status and advanced MET exon 14 skipping mutation-positive lung adenocarcinoma

Por Shea, Meghan, Huberman, Mark S., Costa, Daniel B.
Publicado no J Thorac Oncol (2016)

The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer

Por Gao, Xin, Le, Xiuning, Costa, Daniel B.
Publicado no Expert Rev Anticancer Ther (2016)

Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway

Por Nguyen, Kim-Son H., Kobayashi, Susumu, Costa, Daniel B.
Publicado em 2009

Successful treatment of epidermal growth factor receptor inhibitor–induced alopecia with doxycycline

Por Chen, Chen (Amy), Costa, Daniel B., Wu, Peggy A.
Publicado no JAAD Case Rep (2015)

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers

Por Costa, Daniel B., Kobayashi, Susumu, Tenen, Daniel G., Huberman, Mark S.
Publicado em 2007

Serum concentrations of erlotinib at a dose of 25 mg daily

Por Costa, Daniel B., Yeo, Wee-Lee, Hamada, Akinobu, Kobayashi, Susumu
Publicado em 2010

EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer

Por Ackerman, Allison, Goldstein, Michael A., Kobayashi, Susumu, Costa, Daniel B.
Publicado em 2012

A novel splicing mutation of the α-spectrin gene in the original hereditary pyropoikilocytosis kindred

Por Costa, Daniel B., Lozovatsky, Larisa, Gallagher, Patrick G., Forget, Bernard G.
Publicado em 2005

Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis

Por Folch, Erik, Costa, Daniel B., Wright, Jeffrey, VanderLaan, Paul A.
Publicado no Transl Lung Cancer Res (2015)

Preclinical rationale for use of the clinically-available multitargeted tyrosine kinase inhibitor crizotinib in ROS1 translocated lung cancer

Por Yasuda, Hiroyuki, de Figueiredo-Pontes, Lorena L., Kobayashi, Susumu, Costa, Daniel B.
Publicado em 2012

Case of fatal sickle cell intrahepatic cholestasis despite use of exchange transfusion in an African-American patient.

Por Costa, Daniel B., Miksad, Rebecca A., Buff, Michael S., Wang, Yihong, Dezube, Bruce J.
Publicado em 2006

KRAS mutation analysis helps differentiate between pulmonary metastasis from colon adenocarcinoma in situ and primary lung adenocarcinoma

Por Ortiz, Taylor M., Cohen, David W., Kent, Michael S., Jänne, Pasi A., Costa, Daniel B.
Publicado em 2011

Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations

Por Gaughan, Elizabeth M., Cryer, Sarah K., Yeap, Beow Y., Jackman, David M., Costa, Daniel B.
Publicado em 2012

BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations

Por Costa, Daniel B, Halmos, Balázs, Kumar, Amit, Schumer, Susan T, Huberman, Mark S, Boggon, Titus J, Tenen, Daniel G, Kobayashi, Susumu
Publicado em 2007

Development of Central Nervous System Metastases in Patients with Advanced Non-Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib

Por Heon, Stephanie, Yeap, Beow Y., Britt, Gregory J., Costa, Daniel B., Rabin, Michael S., Jackman, David M., Johnson, Bruce E.
Publicado em 2010